Overview
India faces a massive burden of rare diseases. While the world has about 8,000 such disorders, only 5% have approved medicines. High prices and limited access make treatment unaffordable for most patients. The article outlines how India can become a hub for developing and manufacturing orphan drugs through policy reforms, clinical‑trial participation, and manufacturing incentives.
Key Developments
- Adoption of incentives similar to the Orphan Drug Act to attract foreign firms for trial and production.
- Recognition that India’s large, genetically diverse population can supply patient cohorts for orphan‑drug trials, especially in endogamous communities where conditions like beta‑thalassemia are more common.
- Use of Rule 101 to fast‑track import‑to‑manufacture pathways for already approved orphan drugs.
- Proposal of a production‑linked incentive scheme for orphan‑drug makers, coupled with tax breaks and advanced market commitments.
- Emphasis on robust pharmacovigilance and quality standards to ensure affordable yet safe products.
Important Facts
• Over 1,000 rare genetic disorders have been reported in India, affecting hundreds of millions.
• The U.S. Orphan Drug Act increased approvals from 38 (pre‑1983) to 1,122 by 2022.
• Indian patients often raise ₹9 crore through crowdfunding for a single gene‑therapy case; cumulative annual need exceeds ₹9,000 crore.
• India supplies 47% of U.S. generic prescriptions and 15% of U.S. biosimilars, demonstrating manufacturing capacity.
Exam Relevance
The discussion touches on several GS topics: health policy (GS3), drug‑regulation frameworks (GS3), public‑private partnership models (GS3), and the role of technology in addressing social challenges (GS4). Understanding the Orphan Drug Act and Rule 101 helps answer questions on international health agreements and domestic regulatory reforms. The concept of PLIs links to industrial policy and Make‑in‑India initiatives, a frequent GS3/GS4 theme.
Way Forward
1. Policy Alignment: Enact a dedicated orphan‑drug incentive law mirroring the Orphan Drug Act, with tax credits, market exclusivity, and fast‑track approvals.
2. Clinical‑Trial Integration: Create a national registry for rare‑disease patients, encourage foreign sponsors to run trials in India, and use Rule 101 to avoid duplicate studies.
3. Manufacturing Support: Launch a PLI scheme for orphan‑drug production, provide technology‑transfer assistance, and guarantee procurement through the Central Government Health Scheme and Jan Aushadhi Kendras.
4. Affordability Measures: Allow the Indian government to set price caps for drugs sold domestically or in the Global South, ensuring benefit‑sharing and equitable access.
5. Safety Net: Strengthen pharmacovigilance and post‑marketing surveillance to maintain drug quality while scaling up low‑volume production.
By combining regulatory ease, financial incentives, and a strong patient‑registry network, India can transform from a generic‑drug powerhouse to a global hub for affordable orphan‑drug development.